Moore Capital Management LP Has $15.30 Million Holdings in Revolution Medicines, Inc. $RVMD

Moore Capital Management LP lifted its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) by 46.9% during the second quarter, HoldingsChannel.com reports. The firm owned 81,700 shares of the company’s stock after purchasing an additional 26,100 shares during the period. Moore Capital Management LP’s holdings in Revolution Medicines were worth $15,301,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in RVMD. Contravisory Investment Management Inc. bought a new position in Revolution Medicines in the second quarter valued at approximately $32,000. ABS Investment Management LLC acquired a new stake in shares of Revolution Medicines in the 2nd quarter valued at approximately $337,104,000. Johnson Financial Group Inc. acquired a new stake in shares of Revolution Medicines in the 2nd quarter valued at approximately $37,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Revolution Medicines in the second quarter valued at $41,000. Finally, Silvant Capital Management LLC acquired a new position in Revolution Medicines during the second quarter worth $41,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on RVMD shares. UBS Group raised their target price on shares of Revolution Medicines from $220.00 to $265.00 and gave the company a “buy” rating in a research note on Friday. Royal Bank Of Canada upped their price objective on Revolution Medicines from $203.00 to $251.00 and gave the company an “outperform” rating in a research note on Thursday. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $248.00 price objective on shares of Revolution Medicines in a research report on Thursday. Piper Sandler boosted their target price on Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Finally, Needham & Company LLC boosted their target price on Revolution Medicines from $236.00 to $240.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $198.89.

Revolution Medicines Stock Performance

Shares of Revolution Medicines stock opened at $207.88 on Monday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. The firm has a 50-day moving average of $193.33 and a 200-day moving average of $148.95. Revolution Medicines, Inc. has a 52-week low of $37.56 and a 52-week high of $224.31. The stock has a market cap of $44.56 billion, a PE ratio of -23.57 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period last year, the business earned ($1.31) earnings per share. As a group, sell-side analysts forecast that Revolution Medicines, Inc. will post -8.85 EPS for the current year.

Insider Buying and Selling

In other news, Director Sushil Patel sold 5,580 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the completion of the sale, the director owned 21,656 shares of the company’s stock, valued at approximately $4,071,111.44. This represents a 20.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Stephen Michael Kelsey sold 4,175 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $156.12, for a total transaction of $651,801.00. Following the sale, the insider owned 291,876 shares in the company, valued at $45,567,681.12. This represents a 1.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 212,497 shares of company stock valued at $38,206,486 in the last ninety days. Insiders own 7.60% of the company’s stock.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.